We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to restore balance in the brain by reducing the neuronal hyperexcitability that underlies debilitating brain conditions. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical meaning.

Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with epilepsies and neurological disorders that present with brain conditions.

Program Indication Preclinical Phase 1 Phase 2 Phase 3
+
 		OV329

GABA-aminotransferase inhibitor
  • Conditions with neuronal hyperexcitability
pill icon
+
 		OV350 & KCC2 Library

KCC2 direct activator
  • Neuropsychiatric
  • Neurodevelopmental
  • Neurodegenerative
  • Seizures
  • Pain
IV icon
pill icon
+
 		OV888/GV1011

Selective ROCK2 inhibitor
Collaboration with Graviton logo
  • Cerebral cavernous malformations
  • Undisclosed neurovascular indications
pill icon
IV icon
Drug Indication Stage
OV329

GABA-aminotransferase inhibitor
  • Conditions with neuronal hyperexcitability

Phase 1: Oral
OV350 & KCC2 Platform

KCC2 transporter activator
  • Neuropsychiatric
  • Neurodevelopmental
  • Neurodegenerative
  • Seizures
  • Pain

End of Preclinical: IV

Preclinical: Oral
OV888/GV1011

Selective ROCK2 inhibitor
Collaboration with Graviton logo
  • Cerebral cavernous malformations
  • Undisclosed neurovascular indications

Phase 2: Oral

Preclinical: IV

1Graviton is conducting development of OV888/GV101 capsule through Phase 2, which will be directed by a Joint Development Committee that includes members from both Graviton and Ovid

Publications and Posters ยป